Neptune Technologies & Bioresources
The 10-second takeaway
For the quarter ended May 31 (Q1), Neptune Technologies & Bioresources beat expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP loss per share dropped.
Gross margins improved, operating margins dropped, net margins expanded.
Neptune Technologies & Bioresources booked revenue of $5.9 million. The one analyst polled by S&P Capital IQ wanted to see revenue of $5.8 million on the same basis. GAAP reported sales were 34% higher than the prior-year quarter's $4.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.02. The one earnings estimate compiled by S&P Capital IQ predicted $0.00 per share. GAAP EPS were -$0.02 for Q1 compared to -$0.03 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 58.7%, 680 basis points better than the prior-year quarter. Operating margin was -27.6%, 510 basis points worse than the prior-year quarter. Net margin was -16.0%, 360 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $6.2 million. On the bottom line, the average EPS estimate is -$0.01.
Next year's average estimate for revenue is $26.9 million. The average EPS estimate is -$0.02.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 26 members rating the stock outperform and 145 members rating it underperform. Among 94 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), three give Neptune Technologies & Bioresources a green thumbs-up, and 91 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Neptune Technologies & Bioresources is outperform, with an average price target of $7.27.
Over the decades, small-cap stocks, like Neptune Technologies & Bioresources have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Neptune Technologies & Bioresources to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.